Biotechnology News and Research

RSS

Researchers to test new plantain based food product to treat Crohn's disease

Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea. Researchers are working with biotechnology company, Provexis, to test a new plantain based food product that could treat patients with the disease.

26 Aug 2010

ACT comments on federal fund blocking for embryonic stem cell research

Advanced Cell Technology, Inc. commented today on yesterday's federal court ruling, temporarily blocking federal funding for embryonic stem cell research involving the destruction of embryos.

26 Aug 2010

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Biogen Idec and Elan Corporation, plc today announced data has been published in the Annals of Neurology on an investigational, two-step assay to detect anti-JC virus (JCV) antibodies in human serum and plasma

26 Aug 2010

Plantain and broccoli fiber help in Crohn’s disease: Study

New research suggests that plant fibers in plantains and broccoli can help prevent relapses of Crohn's disease. This disease is a long term disease of the gut that is characterized by inflammation of the lining of the digestive system, with symptoms including diarrhea and abdominal pain. Crohn's disease affects between 400,000 and 600,000 people in North America. Scientists believe that rise in processed food and decrease in fibers in diet could be a reason for rise of incidence of this disease.

25 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

BIO president comments on U.S. District Court injunction on embryonic stem cell research funds

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement today regarding the injunction issued yesterday by a U.S. District Court prohibiting the use of federal funds to support embryonic stem cell research.

25 Aug 2010

Simulations Plus launches Version 7.0 of GastroPlus software for pharmaceutical industry

Simulations Plus, Inc.,a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of Version 7.0 of GastroPlus, the industry's gold standard software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics.

25 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

Dyadic International completes private placement of secured promissory notes

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced that it has completed a private placement of $3,000,000 in convertible subordinated secured promissory notes (the "Notes") with two investors.

25 Aug 2010

ACR Image Metrix praises iCAD on FDA clearance of VeraLook Colon CAD software

ACR Image Metrix™, an imaging contract research organization (CRO) with expertise in imaging research design, techniques and data extraction, congratulates their partner, iCAD, Inc., on obtaining U.S. Food and Drug Administration clearance on its VeraLook™, Colon CAD (Computer-Aided Detection) software.

25 Aug 2010

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.

25 Aug 2010

BioJapan 2010 announces 'Renaissance of Bioindustry' as main theme

BioJapan Organizing Committee will hold the BioJapan 2010 - World Business Forum, scheduled September 29 - October 1 at Pacifico Yokohama, Japan. BioJapan 2010 will revolve around four main topics, 1) Health (Drugs, Medical Devices, and Cosmetics), 2) Environment (Biofuel, Biorefinery, and Biomass Plastics), 3) Food (Functional food), and 4) Clusters & Bio-ventures. At same time, BioJapan will offer various programs integrating exhibitions and seminars.

24 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

NexMed expands patent protection for Prostaglandin E1 -based products in Israel

NexMed, Inc., backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that the Israel Patent Office has issued an allowance notice for NexMed's patent application entitled, "Topical Compositions for Prostaglandin E1 Delivery."

24 Aug 2010

USPTO grants Taligen patent for TT30 lead product candidate

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.

24 Aug 2010

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Precision Antibody™ announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium, an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States.

24 Aug 2010

Researchers develop new instrumentation to simplify testing patients for infectious diseases

Arizona State University researchers have demonstrated a way to dramatically simplify testing patients for infectious diseases and unhealthy protein levels.New testing instrumentation developed by Antonia Garcia and John Schneider promises to make the procedure less costly and produce results in less time.

24 Aug 2010

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Baxter International Inc. today announced a definitive agreement with Kamada Ltd. for exclusive commercial rights to GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid alpha1-proteinase inhibitor, in the United States, Australia, New Zealand and Canada.

From Baxter International Inc. 24 Aug 2010

Researchers find new drug to treat circadian rhythm disorders

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Medical Research Council (MRC) have successfully used a drug to reset and restart the natural 24 hour body clock of mice in the lab. The ability to do this in a mammal opens up the possibility of dealing with a range of human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work.

24 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Biotechnology News and Research

Researchers to test new plantain based food product to treat Crohn's disease

ACT comments on federal fund blocking for embryonic stem cell research

Biogen to publish data on two-step assay for anti-JC virus antibody detection

Plantain and broccoli fiber help in Crohn’s disease: Study

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

BIO president comments on U.S. District Court injunction on embryonic stem cell research funds

Simulations Plus launches Version 7.0 of GastroPlus software for pharmaceutical industry

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Dyadic International completes private placement of secured promissory notes

ACR Image Metrix praises iCAD on FDA clearance of VeraLook Colon CAD software

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

BioJapan 2010 announces 'Renaissance of Bioindustry' as main theme

3SBio and Isotechnika enter strategic agreement for voclosporin in China

NexMed expands patent protection for Prostaglandin E1 -based products in Israel

USPTO grants Taligen patent for TT30 lead product candidate

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Researchers develop new instrumentation to simplify testing patients for infectious diseases

Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Researchers find new drug to treat circadian rhythm disorders

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News